{"id":962774,"date":"2026-05-14T09:41:01","date_gmt":"2026-05-14T13:41:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/"},"modified":"2026-05-14T09:41:01","modified_gmt":"2026-05-14T13:41:01","slug":"endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/","title":{"rendered":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ENDRA Life Sciences Reports Multi-Site Validation of TAEUS<sup>\u00ae<\/sup> Liver Device Demonstrating MRI-like Accuracy and Reproducibility<\/b><\/p>\n<p class=\"bwalignc\"><i>Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway<\/i><\/p>\n<p>ANN ARBOR, Mich.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)<\/b> (\u201cENDRA\u201d or the \u201cCompany\u201d), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS<sup>\u00ae<\/sup> Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites.<\/p>\n<p>\nThe analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver\u2019s thermoacoustic fat fraction measurement closely tracked MRI\u2011PDFF results for patients along the full spectrum of metabolic dysfunction\u2011associated steatotic liver disease (MASLD) and those with elevated body mass index (BMI).<\/p>\n<p>\nKey results in the analysis included:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCorrelation to MRI-PDFF: r=0.90 (combined cohort)<\/p>\n<\/li>\n<li>\nDiagnostic accuracy: AUROC 0.95\u20130.99 at key thresholds<\/p>\n<\/li>\n<li>\nMean error: ~3%, consistent across sites<\/p>\n<\/li>\n<li>\nReproducibility: ICC=0.89 across operators<\/p>\n<\/li>\n<li>\n~90% of measurements within ~5% of MRI values<\/p>\n<\/li>\n<li>\nNo dependence on BMI or body habitus<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cThe multi\u2011site data aggregation shows that TAEUS Liver delivers MRI\u2011like liver fat quantification at the point of patient care, with a strong correlation to MRI\u2011PDFF of 0.90 and no meaningful bias. We believe the combination of this performance coupled with TAEUS Liver\u2019s portability and low cost could make routine liver fat assessment feasible for the more than two billion people worldwide living with MASLD,\u201d said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences.<\/p>\n<p>\nTAEUS Liver is designed to provide MRI\u2011aligned performance in a portable, point\u2011of\u2011care format with an anticipated per\u2011scan cost of under $200, which is less than 8% of a typical MRI\u2011PDFF exam. By enabling frequent, affordable assessments, TAEUS Liver could support routine monitoring of treatment\u2011driven changes in liver fat that are difficult to track with MRI alone. The TAEUS system&#8217;s performance contrasts sharply with ultrasound techniques, which experience high inter-observer variability and subjective interpretations.<\/p>\n<p>\nThese study results support TAEUS Liver\u2019s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by MASLD. TAEUS Liver could be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials. As new metabolic therapies enter the market, the ability to detect small, incremental changes in liver fat without the cost burden of repeated MRI scans becomes increasingly important. ENDRA\u2019s innovative approach with TAEUS combines the precision traditionally associated with expensive imaging modalities with the practical deployment advantages of ultrasound-based systems.<\/p>\n<p><b>About ENDRA Life Sciences Inc.<\/b><\/p>\n<p>\nENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS<sup>\u00ae<\/sup>), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS<sup>\u00ae<\/sup> is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.endrainc.com&amp;esheet=54535764&amp;newsitemid=20260514255247&amp;lan=en-US&amp;anchor=www.endrainc.com&amp;index=1&amp;md5=6ad06bdb2de2187dc94399e988604674\">www.endrainc.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this press release that are not based on historical fact are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements\u2014based on certain assumptions and describing our future plans, strategies, and expectations\u2014can generally be identified by the use of terms such as \u201capproximate,\u201d \u201canticipate,\u201d \u201cattempt,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cfuture,\u201d \u201cgoal,\u201d \u201chope,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.<\/p>\n<p>\nApplicable risks and uncertainties include, among others: expectations regarding our treasury strategy and our ability to execute it successfully; our limited commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in the future; our ability to regain and maintain compliance with Nasdaq listing standards; delays or changes in regulatory requirements, policies, or guidelines; the repeatability of clinical results across larger trial populations; potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for our Thermo Acoustic Enhanced Ultrasound (\u201cTAEUS<sup>\u00ae<\/sup>\u201d) applications; our ability to develop commercially viable products based on our TAEUS<sup>\u00ae<\/sup> technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with regulations from federal, state, local, and foreign governmental agencies; risks related to shifts in regulatory, accounting, or tax treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment company under the Investment Company Act of 1940; our ability to achieve profitability; our dependence on key members of management; and other risks and uncertainties described in the Risk Factors and Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company\u2019s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.<\/p>\n<p>\nYou should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260514255247\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260514255247\/en\/<\/a><\/span><\/p>\n<p><b>Company Contact:<br \/>\n<\/b><br \/>Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@endrainc.com\">investors@endrainc.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.endrainc.com%2F&amp;esheet=54535764&amp;newsitemid=20260514255247&amp;lan=en-US&amp;anchor=www.endrainc.com&amp;index=2&amp;md5=456a74a3f0f56ea37eb1ebd410118cdd\">www.endrainc.com<br \/>\n<\/a><\/p>\n<p><b>Investor Relations Contact:<br \/>\n<\/b><br \/>Yvonne Briggs<br \/>\n<br \/>Alliance Advisors IR<br \/>\n<br \/>(310) 691-7100<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ybriggs@allianceadvisors.com\">ybriggs@allianceadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Michigan United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Medical Devices Health Technology Clinical Trials Research Science Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260514255247\/en\/2804976\/3\/Endra_Life_Sciences.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ANN ARBOR, Mich.&#8211;(BUSINESS WIRE)&#8211;ENDRA Life Sciences Inc. (NASDAQ: NDRA) (\u201cENDRA\u201d or the \u201cCompany\u201d), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS\u00ae Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver\u2019s thermoacoustic fat fraction measurement closely &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962774","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ANN ARBOR, Mich.&#8211;(BUSINESS WIRE)&#8211;ENDRA Life Sciences Inc. (NASDAQ: NDRA) (\u201cENDRA\u201d or the \u201cCompany\u201d), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS\u00ae Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver\u2019s thermoacoustic fat fraction measurement closely &hellip; Continue reading &quot;ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T13:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility\",\"datePublished\":\"2026-05-14T13:41:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/\"},\"wordCount\":1142,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/\",\"name\":\"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-14T13:41:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/","og_locale":"en_US","og_type":"article","og_title":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk","og_description":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ANN ARBOR, Mich.&#8211;(BUSINESS WIRE)&#8211;ENDRA Life Sciences Inc. (NASDAQ: NDRA) (\u201cENDRA\u201d or the \u201cCompany\u201d), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS\u00ae Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver\u2019s thermoacoustic fat fraction measurement closely &hellip; Continue reading \"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-14T13:41:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility","datePublished":"2026-05-14T13:41:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/"},"wordCount":1142,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/","name":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-14T13:41:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260514255247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-demonstrating-mri-like-accuracy-and-reproducibility\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ENDRA Life Sciences Reports Multi-Site Validation of TAEUS\u00ae Liver Device Demonstrating MRI-like Accuracy and Reproducibility"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962774"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962774\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}